— ACTIV-6 trial shows no time-to-recovery benefit with anti-parasitic in mild-to-moderate disease by Ed Susman There were no differences in relief from mild-to-moderate COVID-19 symptoms for patients on ivermectin versus placebo, according to the...
— Action plan has merit, but condition needs its own Operation Warp Speed, advocates say by Shannon Firth More than 2 years after patients started reporting long-lasting symptoms after acute SARS-CoV-2 infection, the U.S. announced its national long COVID plan....
— AAPM&R calls for greater awareness of post-COVID cardiovascular complications among clinicians by Michael DePeau-Wilson Risks for cardiovascular complications, including pulmonary embolism, arterial and venous thromboses, myocardial infarction, and stroke, are...
— Trial website cites supply issues by Jennifer Henderson The ivermectin arm of the U.K.'s PRINCIPLE trial is "currently paused due to temporary supply issues," according to the trial's website. The website does not offer any details on what caused the ivermectin...
— We're not inclined to sit idly as the world suffers by Francesca Lynn Arnoldy A doula is a non-medical care provider who supports people through intense times, such as birth and/or death, complementing any available healthcare services. Humans have assisted other...
— Virginia hospital took issue with article co-authored by Paul Marik, MD by Jennifer Henderson On the same day that one of his papers was retracted, a physician who has been a vocal proponent of ivermectin filed suit against his hospital. Paul Marik, MD,...
— Treatment of plastic waste is not keeping up with demand for plastic products by Lei Lei Wu, Intern COVID-19 has resulted in over 8 million tons of mismanaged plastic waste around the world as of August, researchers reported. Nearly 90% of the excess plastic waste...
— Incidence of autoimmune disease decreased by 25-30% with dietary supplements by Nancy Walsh The use of vitamin D and omega-3 fatty acid supplementation was associated with a decreased likelihood of autoimmune disease in an ancillary analysis of a large randomized...
— When studies with a moderate or greater risk of bias were removed, survival benefit vanished by Kristina Fiore share to facebookshare to twittershare to linkedinemail article Some authors of a widely reported meta-analysis of ivermectin studies that was...
— A story of knowledge and recovery by Paul Gardener, MD I'm 65, and I'm fit and well. When COVID struck, I was enjoying life. I was doing lots of running and cycling. I felt I was titanium-plated in some ways. The disease was traveling very rapidly through the U.K. I...
— Study shows importance of vaccination to prevent severe disease, even among previously infected by Molly Walker n people hospitalized for COVID-like respiratory illnesses, unvaccinated adults who previously had COVID-19 were over five times more likely to test...
— Systematic vaccination is necessary but may not be sufficient for those at high risk by Daniel Teres, MD, Diana M. Stone, PhD, MPH, DVM, and Martin A. Strosberg, PhD, MPH he recent surge of COVID-19 in the southern U.S. in summer and early fall was...
— Researchers urge caution, but a clearer picture starts to emerge by Molly Walker A so-called "mix and match" COVID vaccine series using a different booster than the primary series was safe and produced an increase in immune response comparable to or greater than...
— New study suggests arginine supplementation may help in cases of severe illness by Heath McAnally, MD, MSPH Back in April 2020, after evaluating a number of diverse data sources including bench studies, clinical trials, and epidemiologic investigations pertaining to...
— For those on active therapy, 80% had increased antibody levels, study showed by Mike Bassett A third dose of Pfizer's COVID-19 vaccine (BNT162b2; Comirnaty) could offer increased protection for cancer patients on active treatment, a new study suggested, as these...